Catalyst Pharmaceuticals, Inc.
CPRX
$31.16
$0.020.06%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 11.65% | 19.78% | 25.56% | 28.55% | 29.97% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 11.65% | 19.78% | 25.56% | 28.55% | 29.97% |
| Cost of Revenue | 8.06% | 22.66% | 32.08% | -36.44% | -39.89% |
| Gross Profit | 12.36% | 19.20% | 24.32% | 62.50% | 68.71% |
| SG&A Expenses | 10.38% | 9.01% | 5.09% | 12.05% | 17.75% |
| Depreciation & Amortization | 1.28% | 0.32% | 0.77% | 3.16% | 5.65% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 8.58% | 11.67% | 11.49% | -9.61% | -8.93% |
| Operating Income | 15.68% | 32.11% | 48.74% | 183.45% | 195.38% |
| Income Before Tax | 14.70% | 31.10% | 51.38% | 190.68% | 199.54% |
| Income Tax Expenses | 22.95% | 32.11% | 48.35% | 149.08% | 188.66% |
| Earnings from Continuing Operations | 12.15% | 30.78% | 52.36% | 206.19% | 203.07% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 12.15% | 30.78% | 52.36% | 206.19% | 203.07% |
| EBIT | 15.68% | 32.11% | 48.74% | 183.45% | 195.38% |
| EBITDA | 13.62% | 26.94% | 40.27% | 129.68% | 136.03% |
| EPS Basic | 9.66% | 27.01% | 44.41% | 196.96% | 178.13% |
| Normalized Basic EPS | 14.88% | 29.88% | 42.91% | 172.31% | 171.58% |
| EPS Diluted | 10.95% | 29.18% | 45.62% | 205.24% | 190.43% |
| Normalized Diluted EPS | 16.29% | 31.60% | 44.70% | 182.21% | 183.57% |
| Average Basic Shares Outstanding | 2.39% | 3.24% | 5.53% | 7.63% | 9.65% |
| Average Diluted Shares Outstanding | 1.12% | 1.85% | 4.24% | 8.07% | 10.04% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |